CN103222953B - 一种盐酸法舒地尔注射液组合物及其制备方法 - Google Patents
一种盐酸法舒地尔注射液组合物及其制备方法 Download PDFInfo
- Publication number
- CN103222953B CN103222953B CN201310159617.3A CN201310159617A CN103222953B CN 103222953 B CN103222953 B CN 103222953B CN 201310159617 A CN201310159617 A CN 201310159617A CN 103222953 B CN103222953 B CN 103222953B
- Authority
- CN
- China
- Prior art keywords
- injection
- preparation
- fasudil hydrochloride
- value
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 40
- 239000007924 injection Substances 0.000 title claims abstract description 40
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960002435 fasudil Drugs 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 32
- 230000001954 sterilising effect Effects 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 239000003610 charcoal Substances 0.000 claims description 20
- 239000008215 water for injection Substances 0.000 claims description 19
- 239000003708 ampul Substances 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 239000005388 borosilicate glass Substances 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229940105082 medicinal charcoal Drugs 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 6
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 229910021645 metal ion Inorganic materials 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229950004777 sodium calcium edetate Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000007774 longterm Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 4
- 229960001305 cysteine hydrochloride Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310159617.3A CN103222953B (zh) | 2013-05-03 | 2013-05-03 | 一种盐酸法舒地尔注射液组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310159617.3A CN103222953B (zh) | 2013-05-03 | 2013-05-03 | 一种盐酸法舒地尔注射液组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103222953A CN103222953A (zh) | 2013-07-31 |
CN103222953B true CN103222953B (zh) | 2014-03-12 |
Family
ID=48833752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310159617.3A Active CN103222953B (zh) | 2013-05-03 | 2013-05-03 | 一种盐酸法舒地尔注射液组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103222953B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104069063B (zh) * | 2014-05-22 | 2019-03-26 | 西藏九瑞健康股份有限公司 | 盐酸法舒地尔药物组合物及其制备方法 |
CN105168224B (zh) * | 2015-09-24 | 2018-11-13 | 辰欣药业股份有限公司 | 一种盐酸法舒地尔注射液及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101194123B1 (ko) * | 2004-03-16 | 2012-10-24 | 아사히 가세이 파마 가부시키가이샤 | 패수딜 함유 제제 및 그 안정성을 개선하는 방법 |
CN101008637B (zh) * | 2007-01-11 | 2010-07-21 | 天津红日药业股份有限公司 | 一种盐酸法舒地尔注射液的质量控制方法 |
CN102008433A (zh) * | 2010-12-01 | 2011-04-13 | 广东三信药业有限公司 | 一种改善稳定性的法舒地尔盐注射液及其制备方法 |
CN102266343A (zh) * | 2011-09-05 | 2011-12-07 | 天津市汉康医药生物技术有限公司 | 供注射用盐酸法舒地尔药物组合物 |
-
2013
- 2013-05-03 CN CN201310159617.3A patent/CN103222953B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103222953A (zh) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768091B (zh) | 碳酸氢钠注射液及其制备方法 | |
CN101167730B (zh) | 一种复方倍他米松混悬型注射液 | |
CN103222953B (zh) | 一种盐酸法舒地尔注射液组合物及其制备方法 | |
CN101874770A (zh) | 一种克林霉素磷酸酯注射液及其制备方法 | |
CN103126978A (zh) | 一种盐酸氨溴索注射液的制备方法 | |
CN102397245A (zh) | 一种盐酸尼卡地平葡萄糖注射液 | |
CN103340866A (zh) | 一种哌拉西林钠和他唑巴坦钠的药物组合物及其制备方法 | |
CN104840418B (zh) | 一种盐酸法舒地尔注射液组合物及其制备方法 | |
CN102784382A (zh) | 一种阿加曲班药物组合物及其制备方法和应用 | |
CN103463614B (zh) | 一种阿加曲班注射液及其制备方法 | |
CN100336508C (zh) | 一种稳定的帕洛诺司琼注射液 | |
CN102151257A (zh) | 一种白消安注射剂及其制备方法 | |
CN104000827B (zh) | 一种含有活性成分盐酸纳美芬的药物组合物 | |
CN114288385B (zh) | 一种醋酸奥曲肽制剂的制备方法 | |
CN104997728B (zh) | 一种盐酸纳美芬注射液药物组合物及其制备方法 | |
CN101199514A (zh) | 酮咯酸氨丁三醇注射剂及其制备方法 | |
CN105168224A (zh) | 一种盐酸法舒地尔注射液及其制备方法 | |
CN106539755B (zh) | 一种盐酸法舒地尔注射液及其制备方法 | |
CN100367962C (zh) | 一种稳定的帕洛诺司琼注射液及其制备方法 | |
CN103405384A (zh) | 氨甲环酸的药物组合物 | |
CN102846561A (zh) | 一种供注射用的奥扎格雷钠药物组合物 | |
JP2008231025A (ja) | マレイン酸フルボキサミン錠剤 | |
CN102085180A (zh) | 一种盐酸多巴酚丁胺水针剂及其制备方法 | |
CN103830164A (zh) | 盐酸莫西沙星注射液及其制备方法 | |
CN106943342B (zh) | 一种含有阿加曲班的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fasudil hydrochloride injection composition and its preparation method Effective date of registration: 20140619 Granted publication date: 20140312 Pledgee: Chengdu high investment financing Company limited by guarantee Pledgor: Chengdu Easton Pharmaceutical Co., Ltd. Registration number: 2014510000015 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150709 Granted publication date: 20140312 Pledgee: Chengdu high investment financing Company limited by guarantee Pledgor: Chengdu Easton Pharmaceutical Co., Ltd. Registration number: 2014510000015 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 611731 Chengdu province high tech Zone, west of the source road, No. 8, No. Patentee after: CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Address before: 611731 Chengdu province high tech Zone, west of the source road, No. 8, No. Patentee before: Chengdu Easton Pharmaceutical Co., Ltd. |